RE:Stock priceIf the stock price goes much lower they won't qualify for the NASDAQ ... I think $4 US is the minimum. So they might have to do a reverse split before listing ??? That should get the SP moving!
-LT
jeffm34 wrote: Any speculation of a possible financing needed soon will put downward pressure on the stock. A Nasdaq listing without a financing will be useless. Why would any company promote the stock if there's nothing in it for them. I'm sure there would be no shortage of companies willing to do a financing along with a Nasdaq listing with the stock at this price level.
The company needs to find an alternative plan. What they need is a share buyback plan but they don't have the resources for that. What about selling marketing rights of Egrifta and Trogarzo and sortilin receptor platform in smaller less important market territories? There is a company less than a mile from Thera that does exactly that. They are sitting on $700M in cash just waiting to license products.
Knight Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, in-licensing, out-licensing, marketing and distributing innovative prescription pharmaceuticals, consumer health products and medical devices in Canada and select international markets. Knight is publicly traded on the TSX (GUD).